MedTrace Logo

Impact of Gamma-OH on Sleep in ICU Patients

NCT04224246 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-02-20

No results posted yet for this study

Summary

The Main objective of the trial is to assess sleep quality with Gamma-OH® in patients difficult to wean from mechanical ventilation in the ICU.

Conditions

  • Weaning from Mechanical Ventilation

Interventions

DRUG

Gamma Hydroxybutyrate

Gamma-OH® will be administered intravenously at a dose of 20 mg/kg/h for 6 hours

Sponsors & Collaborators

  • Poitiers University Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-27
Primary Completion
2023-02-09
Completion
2023-02-09

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04224246 on ClinicalTrials.gov